High-Grade Glioma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035

Market Overview:

The top 7 (US, EU4, UK, and Japan) high-grade glioma markets are expected to exhibit a CAGR of 3.63% during 2025-2035.

The high-grade glioma market has been comprehensively analyzed in IMARC's new report titled "High-Grade Glioma Market Size, Epidemiology, In-Market Drugs Sales, Pipeline Therapies, and Regional Outlook 2025-2035". High-grade glioma refers to a type of malignant brain tumor that occurs in the glial cells, which are supportive cells in the central nervous system. This disease is considered the most severe and aggressive form of glioma. It is often characterized by rapidly dividing cancer cells, extensive infiltration into nearby brain tissues, and a high potential to spread to other parts of the brain. The symptoms of this ailment may vary depending on the tumor's location but commonly include headaches, seizures, cognitive decline, changes in personality, visual disturbances, mood swings, irritability, depression, weakness, paralysis, difficulty controlling movement in the limbs, a loss of sensation in certain areas of the body, etc. The diagnosis of high-grade gliomas typically involves a combination of a medical history review and a physical examination. A neurological assessment may be conducted to evaluate brain function and determine the potential impact of the tumor on various neurological abilities. The healthcare provider may further perform several diagnostic studies, such as magnetic resonance imaging (MRI), to visualize the brain and identify any abnormal growths.

The increasing cases of genetic mutations and inherited conditions, which alter proteins in ways that cause healthy tissues to become cancerous, are primarily driving the high-grade glioma market. In addition to this, the rising prevalence of immune system dysfunction, resulting in the proliferation of aberrant cells and the formation of tumors, is also creating a positive outlook for the market. Moreover, the widespread adoption of radiation therapy, since it involves the application of high-energy X-rays to kill tumors or prevent the progression of the disease, is further bolstering the market growth. Apart from this, the inflating utilization of anti-angiogenic drugs, like bevacizumab, that target vascular endothelial growth factor (VEGF) to inhibit the formation of abnormal blood vessels, thereby limiting the supply of nutrients and oxygen in tumors, is acting as another significant growth-inducing factor. Additionally, the emerging popularity of stereotactic radiosurgery to treat recurrent disease conditions, owing to its several associated benefits, such as focused delivery, non-invasiveness, and reduced treatment duration, is expected to drive the high-grade glioma market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the high-grade glioma market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for high-grade glioma and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the high-grade glioma market in any manner.

Time Period of the Study

• Base Year: 2024
• Historical Period: 2019-2024
• Market Forecast: 2025-2035

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the high-grade glioma market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the high-grade glioma market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current high-grade glioma marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the high-grade glioma market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2024 and how are they expected to perform till 2035?
• What was the country-wise size of the high-grade glioma across the seven major markets in 2024 and what will it look like in 2035?
• What is the growth rate of the high-grade glioma across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?

Epidemiology Insights

• What is the number of incident cases (2019-2035) of high-grade glioma across the seven major markets?
• What is the number of incident cases (2019-2035) of high-grade glioma by age across the seven major markets?
• What is the number of incident cases (2019-2035) of high-grade glioma by gender across the seven major markets?
• What is the number of incident cases (2019-2035) of high-grade glioma by type across the seven major markets?
• How many patients are diagnosed (2019-2035) with high-grade glioma across the seven major markets?
• What is the size of the high-grade glioma patient pool (2019-2024) across the seven major markets?
• What would be the forecasted patient pool (2025-2035) across the seven major markets?
• What are the key factors driving the epidemiological trend high-grade glioma of?
• What will be the growth rate of patients across the seven major markets?

High-Grade Glioma: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for high-grade glioma drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the high-grade glioma market?
• What are the key regulatory events related to the high-grade glioma market?
• What is the structure of clinical trial landscape by status related to the high-grade glioma market?
• What is the structure of clinical trial landscape by phase related to the high-grade glioma market?
• What is the structure of clinical trial landscape by route of administration related to the high-grade glioma market?